Wen-I Lee1, Jing-Long Huang, Kuo-Wei Yeh, Min-Jay Yang, Ming-Chi Lai, Li-Chen Chen, Liang-Shiou Ou, Tsung-Chieh Yao, Syh-Jae Lin, Tang-Her Jaing, Shih-Hsiang Chen, Meng-Ying Hsieh, Hsin-Hui Yu, Yin-Hsiu Chien, Shyh-Dar Shyur. 1. From the *Primary Immunodeficiency Care And Research (PICAR) Institute, Chang Gung Children's Hospital; †Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Chang Gung University College of Medicine and Children's Hospital, Taoyuan; ‡Department of Pediatrics, Chi Mei Hospital, Tainan; §Department of Pediatrics, Division of Hematology and Oncology, Chang Gung Children's Hospital; ¶Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan; ‖Department of Pediatrics, National Taiwan University Hospital; and **Department of Pediatrics, Mackay Memorial Hospital, Taipei, Taiwan.
Abstract
OBJECTIVES: Hyper IgM syndrome (HIGM), characterized by recurrent infections, low serum IgG and IgA, normal or elevated IgM, defective class switch recombination and somatic hypermutation, are heterogeneous disorders with at least 6 distinct molecular defects, including the CD40 ligand (CD40L) and the nuclear factor κB essential modulator (NEMO, also known as IKKγ) genes (both X-linked), the CD40, activation-induced cytidine deaminase (AICDA or AID), uracil-DNA glycosylase genes (autosomal recessive) and IκBα (IKBA) (autosomal dominant). Our objective was to determine the molecular basis and clinical features of Taiwanese patients with the HIGM phenotype. METHODS: Clinical manifestations and candidate genes were analyzed in a nationwide population-based study. RESULTS: Among 14 patients (12 unrelated families) since 2003, 10 patents were identified (8 families) with CD40L mutations, including 2 novel deletions of "A" nucleotide (Del 347A and Del 366A), both frameshift and stop at the 127th location; 1 novel AID deletion mutation lack of the 37thAsp and 38th Ser; 1 ataxia-telangiectasia mutation; and 1 deletion of chromosome 1q42. An adult-onset patient with mutant (Thr254Met)CD40L had approximately 30% detectable affinity and therefore less severity. Memory B cells decreased in patients with CD40L and activation-induced cytidine deaminase mutations. Three mortalities encompassed renal cell carcinoma in 1 patient with (Tyr169Asn)CD40L, pneumothorax in 1 with (Tyr140Stop)CD40L and pneumonia after chemotherapy in an ataxia-telangiectasia patient. One patient without detectable genetic defects but normal lymphocyte proliferation resembled the mild form of common variable immune deficiency phenotype. CONCLUSIONS: In contrast to those with AICDA mutation, small chromosome 1 q42 deletion and unknown genetic defect, the majority (10/14; 71.4%) with CD40L mutations except (Thr254Met) and an ataxia-telangiectasia patient had the severe form of HIGM phenotype.
OBJECTIVES:Hyper IgM syndrome (HIGM), characterized by recurrent infections, low serum IgG and IgA, normal or elevated IgM, defective class switch recombination and somatic hypermutation, are heterogeneous disorders with at least 6 distinct molecular defects, including the CD40 ligand (CD40L) and the nuclear factor κB essential modulator (NEMO, also known as IKKγ) genes (both X-linked), the CD40, activation-induced cytidine deaminase (AICDA or AID), uracil-DNA glycosylase genes (autosomal recessive) and IκBα (IKBA) (autosomal dominant). Our objective was to determine the molecular basis and clinical features of Taiwanese patients with the HIGM phenotype. METHODS: Clinical manifestations and candidate genes were analyzed in a nationwide population-based study. RESULTS: Among 14 patients (12 unrelated families) since 2003, 10 patents were identified (8 families) with CD40L mutations, including 2 novel deletions of "A" nucleotide (Del 347A and Del 366A), both frameshift and stop at the 127th location; 1 novel AID deletion mutation lack of the 37thAsp and 38th Ser; 1 ataxia-telangiectasia mutation; and 1 deletion of chromosome 1q42. An adult-onset patient with mutant (Thr254Met)CD40L had approximately 30% detectable affinity and therefore less severity. Memory B cells decreased in patients with CD40L and activation-induced cytidine deaminase mutations. Three mortalities encompassed renal cell carcinoma in 1 patient with (Tyr169Asn)CD40L, pneumothorax in 1 with (Tyr140Stop)CD40L and pneumonia after chemotherapy in an ataxia-telangiectasiapatient. One patient without detectable genetic defects but normal lymphocyte proliferation resembled the mild form of common variable immune deficiency phenotype. CONCLUSIONS: In contrast to those with AICDA mutation, small chromosome 1 q42 deletion and unknown genetic defect, the majority (10/14; 71.4%) with CD40L mutations except (Thr254Met) and an ataxia-telangiectasiapatient had the severe form of HIGM phenotype.
Authors: M Teresa de la Morena; David Leonard; Troy R Torgerson; Otavio Cabral-Marques; Mary Slatter; Asghar Aghamohammadi; Sharat Chandra; Luis Murguia-Favela; Francisco A Bonilla; Maria Kanariou; Rongras Damrongwatanasuk; Caroline Y Kuo; Christopher C Dvorak; Isabelle Meyts; Karin Chen; Lisa Kobrynski; Neena Kapoor; Darko Richter; Daniela DiGiovanni; Fatima Dhalla; Evangelia Farmaki; Carsten Speckmann; Teresa Español; Anna Shcherbina; Imelda Celine Hanson; Jiri Litzman; John M Routes; Melanie Wong; Ramsay Fuleihan; Suranjith L Seneviratne; Trudy N Small; Ales Janda; Liliana Bezrodnik; Reinhard Seger; Andrea Gomez Raccio; J David M Edgar; Janet Chou; Jordan K Abbott; Joris van Montfrans; Luis Ignacio González-Granado; Nancy Bunin; Necil Kutukculer; Paul Gray; Gisela Seminario; Srdjan Pasic; Victor Aquino; Christian Wysocki; Hassan Abolhassani; Morna Dorsey; Charlotte Cunningham-Rundles; Alan P Knutsen; John Sleasman; Beatriz Tavares Costa Carvalho; Antonio Condino-Neto; Eyal Grunebaum; Helen Chapel; Hans D Ochs; Alexandra Filipovich; Mort Cowan; Andrew Gennery; Andrew Cant; Luigi D Notarangelo; Chaim M Roifman Journal: J Allergy Clin Immunol Date: 2016-09-30 Impact factor: 10.793
Authors: Tábata T França; Luiz F B Leite; Tiago A Maximo; Christiane G Lambert; Nuria B Zurro; Wilma C N Forte; Antonio Condino-Neto Journal: Front Pediatr Date: 2018-05-04 Impact factor: 3.418
Authors: Waleed Al-Herz; Janet Chou; Ottavia Maria Delmonte; Michel J Massaad; Wayne Bainter; Riccardo Castagnoli; Christoph Klein; Yenan T Bryceson; Raif S Geha; Luigi D Notarangelo Journal: Front Immunol Date: 2019-01-15 Impact factor: 7.561
Authors: Luca Trotta; Timo Hautala; Sari Hämäläinen; Jaana Syrjänen; Hanna Viskari; Henrikki Almusa; Maija Lepisto; Meri Kaustio; Kimmo Porkka; Aarno Palotie; Mikko Seppänen; Janna Saarela Journal: Eur J Hum Genet Date: 2016-05-04 Impact factor: 4.246